Antipeptide Antibody Responses following Intranasal Immunization: Effectiveness of Mucosal Adjuvants

Toxicity is a major factor limiting the development and use of potent adjuvants for human mucosally delivered vaccines. Novel adjuvant formulations have recently become available, and in the present study two have been used for intranasal immunization with a synthetic peptide immunogen (MAP-M2). Thi...

Celý popis

Podrobná bibliografie

Vydáno v:	Infect Immun
Hlavní autoři:	Olszewska, Wieslawa, Partidos, Charalambos D., Steward, Michael W.
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	American Society for Microbiology (ASM) 2000
Témata:	Microbial Immunity and Vaccines
On-line přístup:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC101701/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/10948106/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/iai.68.9.4923-4929.2000
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!